^
Association details:
| Biomarker: | EGFR G719X |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug Class: | Tyrosine kinase inhibitor |
| Direction: | Resistant |
Evidence:
Source:
Title:
Associated factors for poor response in advanced EGFR-mutated NSCLC patients under tirosine kinasa inhibitors: Peruvian real-world data
Published date:
05/19/2021
Excerpt:
...advanced NSCLC patients harboring EGFR mutations that have received TKI as first line therapy…EGFR uncommon mutations (de novo exon20 T790 mutations and exon18 G719X substitution)...odds ratio for poor response was more associated with uncommon mutations (OR = 8.21, IC95% = 1.94-97.18; p = 0.025)...According to our data, poor response is associated with uncommon EGFR mutations...
DOI:
10.1200/JCO.2021.39.15_suppl.e21214
